Taken together, these results suggest that PHLDB3 contributes to the resistance of cancer cells to chemotherapeutic drugs, particularly in wild type p53-containing cancer cells or those cancer cells with amplified PHLDB3, implying that this protein might be a potential molecule target for future development of an anti-cancer therapy. The gene discussed is TP53; the disease is cancer.